Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights
05:25pm, Thursday, 23'rd Apr 2026
SAN DIEGO--(BUSINESS WIRE)---- $NKTR #Nektar--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ
SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closi
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Thursday, 23'rd Apr 2026
LOS ANGELES, April 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportu
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
09:50am, Thursday, 23'rd Apr 2026
LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
The Red Flags: What Insiders Allegedly Knew Before Shareholders Did NEW YORK, April 23, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against Nektar Therapeuti
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Filed Against Nektar Therapeutics (NKTR)
08:01am, Thursday, 23'rd Apr 2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
New York, New York--(Newsfile Corp. - April 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February
Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA NEW YORK, April 22, 2026 /PRNewswire/ -- IMPORTANT DATE: May 5, 2026. Investors who purchased Nektar Therapeutics (NASDAQ: NKTR)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
01:27am, Wednesday, 22'nd Apr 2026
NEW YORK, April 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and De
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
09:30pm, Tuesday, 21'st Apr 2026
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunothera
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 an
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
03:59pm, Tuesday, 21'st Apr 2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and certa
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Tuesday, 21'st Apr 2026
New York, New York--(Newsfile Corp. - April 21, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed again
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
11:41am, Tuesday, 21'st Apr 2026
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
